Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: a mathematical model

DOI10.1016/J.JTBI.2022.111297zbMATH Open1504.92060OpenAlexW4303985981MaRDI QIDQ2109247FDOQ2109247

Authors: Nourridine Siewe, A. Friedman 

Publication date: 20 December 2022

Published in: Journal of Theoretical Biology (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/j.jtbi.2022.111297

Recommendations

• Mathematical modeling of an immune checkpoint inhibitor and its synergy with an immunostimulant
• A mathematical model of tumor-immune interactions with an immune checkpoint inhibitor
• Mathematical modeling for the combination treatment of IFN-\(\gamma\) and anti-PD-1 in cancer immunotherapy
• Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor
• Combination therapy for cancer with IL-27 and anti-PD-1: A simplified mathematical model

zbMATH Keywords

immune checkpoint inhibitorcabiralizumabcancer model frameworkCSF-1 blockadenivolumabpexidartinib

Mathematics Subject Classification ID

Medical applications (general) (92C50) PDEs in connection with biology, chemistry and other natural sciences (35Q92)

Cites Work

• Overcoming drug resistance to BRAF inhibitor

Cited In (11)

• Bifurcations of a cancer immunotherapy model explaining the transient delayed response and various other responses
• Mathematical modeling for the combination treatment of IFN-\(\gamma\) and anti-PD-1 in cancer immunotherapy
• Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor
• A mathematical model of tumor-immune interactions with an immune checkpoint inhibitor
• Combination therapy for cancer with IL-27 and anti-PD-1: A simplified mathematical model
• Different mechanisms of CD200-CD200R induce diverse outcomes in cancer treatment
• Mathematical modeling of an immune checkpoint inhibitor and its synergy with an immunostimulant
• Predicting resistance and pseudoprogression: are minimalistic immunoediting mathematical models capable of forecasting checkpoint inhibitor treatment outcomes in lung cancer?
• Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer
• Modeling LSD1-mediated tumor stagnation
• Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy

This page was built for publication: Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: a mathematical model

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2109247)